These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10119189)

  • 41. Implementation and cost analysis of a syringe pump system for intermittent i.v. drug delivery.
    Colangelo A; Clark ST; Janousek JP
    Am J Hosp Pharm; 1985 Mar; 42(3):581-4. PubMed ID: 3985021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
    Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
    Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focus and impact of pharmacists' interventions.
    Strong DK; Tsang GW
    Can J Hosp Pharm; 1993 Jun; 46(3):101-8. PubMed ID: 10126864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ergonomic and economic aspects of total parenteral nutrition.
    Genton L; Mühlebach S; Dupertuis YM; Pichard C
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):149-54. PubMed ID: 16477180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Automated compounder for adding ingredients to parenteral nutrient base solutions.
    Dickson LB; Somani SM; Herrmann G; Abramowitz PW
    Am J Hosp Pharm; 1993 Apr; 50(4):678-82. PubMed ID: 8470683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy.
    Algozzine GJ; Sprenger RL; Caselnova DA; Proper P
    Am J Hosp Pharm; 1989 Jun; 46(6):1183-4. PubMed ID: 2568750
    [No Abstract]   [Full Text] [Related]  

  • 48. Minimizing i.v. admixture waste in a 70-bed hospital.
    Tullio CJ
    Hosp Pharm; 1987 Oct; 22(10):994, 997, 1001. PubMed ID: 10284567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. More efficient system for preparing total parenteral nutrient solutions.
    Condella F; Baptista RJ; Griffin RE
    Am J Hosp Pharm; 1983 Dec; 40(12):2146-9. PubMed ID: 6419587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost comparison of two systems for intermittent intravenous administration of small-volume injections.
    Reilly RT; Strand LM; Bair JN
    Am J Hosp Pharm; 1985 Feb; 42(2):323-8. PubMed ID: 3976678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One hospital's success with medication budget control.
    McLean W; Simon V
    Leadersh Health Serv; 1994; 3(2):6-10. PubMed ID: 10133642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
    Sonnenberg A; Pauly MP; Levenson SD; Schwartz JS
    Am J Manag Care; 1999 Jan; 5(1):53-9. PubMed ID: 10345967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case studies of pharmacy involvement in hospital-based home health care. St. Joseph Hospital and Health Care Center.
    Linggi AJ; Pelham LD; Norwood MR; Kelley KA
    Am J Hosp Pharm; 1986 Feb; 43(2):392-6. PubMed ID: 3082197
    [No Abstract]   [Full Text] [Related]  

  • 54. Ciprofloxacin use under a reserved drug and stepdown promotion program.
    Frighetto L; Martinusen SM; Mamdani F; Jewesson PJ
    Can J Hosp Pharm; 1995 Feb; 48(1):35-42. PubMed ID: 10141061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
    Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA
    Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
    [No Abstract]   [Full Text] [Related]  

  • 56. Nutritional support of the hospitalized patient: a team approach.
    Jones JS; Tidwell B; Travis J; Spencer T; Phillips P; Burford B
    J Miss State Med Assoc; 1995 Apr; 36(4):91-9. PubMed ID: 7776363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complications and cost associated with parenteral nutrition delivered to hospitalized patients through either subclavian or peripherally-inserted central catheters.
    Cowl CT; Weinstock JV; Al-Jurf A; Ephgrave K; Murray JA; Dillon K
    Clin Nutr; 2000 Aug; 19(4):237-43. PubMed ID: 10952794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacy program to reduce parenteral nutrition costs.
    Roberts MJ; Teasley KM; Roberts AW
    Am J Hosp Pharm; 1981 Oct; 38(10):1519-20. PubMed ID: 6794366
    [No Abstract]   [Full Text] [Related]  

  • 59. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.